Linda W. Martin, MD, MPH
Dr. Linda W. Martin is the Chief of Thoracic Surgery at UVA Health and UVA Comprehensive Cancer Center in Charlottesville, Virginia. She specializes in thoracic malignancies of all kinds, including lung cancer, pleural mesothelioma, and esophageal cancer, though her practice also includes the treatment of patients with benign lung and esophageal disease.[1]
Education and Career
Dr. Martin earned a Bachelor of Science degree at the University of California, Los Angeles, then earned her medical degree from the University of California, San Diego. She began an internship and residency in General Surgery at the University of Minnesota, then transferred to complete the training at the University of California, San Francisco. She followed this with a fellowship in General Thoracic Surgery with Thoracic Track at M.D. Anderson Cancer Center in Houston, Texas, and later completed a post-doctorate master’s degree in Public Health from the University of Texas, Houston.[1]
She joined the UVA Comprehensive Cancer Center as an associate professor of Surgery and is now Chief of Thoracic Surgery.
Professional Memberships and Activities
Dr. Martin is an active member of numerous professional medical societies and organizations, including:[2]
- American Association for Thoracic Surgery
- Cardiothoracic Surgery Network
- General Thoracic Surgical Club
- Southern Thoracic Surgical Association
- The Society of Thoracic Surgeons
- Women in Thoracic Surgery
Research
Dr. Martin is active in research and works to offer clinical trial access to patients who qualify. Much of her responsibility at UVA includes the design and implementation of studies, and she serves on several committees of the Alliance for Clinical Trials in Oncology, an NCI-sponsored group. She also works with other health professionals, including anesthesiologists and nursing staff, to improve recovery and shorten patient stays following thoracic surgery.[1]
Clinical trials she’s been involved in include:[2]
NCT04062708 Alliance Foundation Trial 46: CHIO3: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Lung Cancer. Study Chair.
NCT03604991: ECOG-ACRIN EA2174, “A Phase II Study of Peri-operative Nivolumab and lpilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma. Principal Investigator: Jennifer Eads.
Role: Alliance Study Champion/National Co-Chair.
NCT 02856581 Alliance Trial A211401 Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients with Newly Diagnosed Lung Cancer Who Smoke Cigarettes (closed)
NCT02468024 Stablemates Trial: Sublobar Resection vs. SBRT for high-risk operable early-stage lung cancer (closed)
NCT03425643 Keynote 671: Efficacy and Safety of Pembrolizumab with Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants with Resectable stage IIB or IIIA Non-Small Cell Lung Cancer (closed)
NCT02194738 ALCHEMIST Trial and related trials (ANVIL, et al.)
NCT03228537 SWOG 1619: Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma (closed)
NCT04241315 ELUCIDATE: Enabling LUng Cancer IDentification Using folATE Receptor Targeting. On Target Laboratories. Steering Committee, site PI. (closed)
